Monte Rosa Therapeutic (GLUE) UBS Global Biopharma Conference 2026 summary
Event summary combining transcript, slides, and related documents.
UBS Global Biopharma Conference 2026 summary
16 Nov, 2026Molecular glue platform
QuEEN molecular glue degraders reshape a ubiquitin ligase surface to induce interaction with target proteins; the approach is designed to reach targets considered undruggable by other modalities.
VAV1 is a key example of an otherwise undruggable target being pursued with this platform.
NEK7 and cardiovascular inflammation
MRT-8102 degrades NEK7, an essential NLRP3 inflammasome scaffolding protein; cellular proteomics showed NEK7 degradation without other detected protein degradation across tested cell types.
The proposed advantages over direct NLRP3 inhibition are selective pathway shutdown and deeper, more prolonged pharmacodynamic effects, which could support safety and efficacy.
Management maintained conviction in upstream NLRP3 targeting after the negative ZEUS result, attributing it in part to downstream IL-6 targeting and trial-population considerations; Novartis and Roche have initiated Phase II NLRP3 inhibitor trials in ASCVD, and Novo Nordisk started a Phase I trial.
GFORCE-1’s four-week cohort showed calprotectin and HMGB1 returning to normal physiological levels; 5–40 mg cohorts had similar biomarker modulation.
GFORCE-2 and other 8102 indications
GFORCE-2 is planned to start in H1 2027, with six months of treatment in coronary artery disease; objectives include correlating fat attenuation index (FAI) with DAMPs, hsCRP and NLRP3 genetics, and assessing FAI change.
Management views FAI as a way to identify residual plaque inflammation; hsCRP is expected to remain useful for therapeutic response, with its predictive value dependent on targeting the right pathway node.
The Phase II gout study will enroll 60 patients across cohorts and assess prevention of recurrent flares after acute-flare management; readout is expected in H2 2027, with Phase III to follow if successful.
An HS trial is planned for H1 2027, after GFORCE-2; further preparation is underway following mixed prior trial patterns, including inverse dose responses in some Phase II studies.
Latest events from Monte Rosa Therapeutic
- Gout data are guided for H2 2027 as the VAV1 program expands.GLUE
Jefferies Global Healthcare Conference - NEK7, VAV1 and oncology programs advance across clinical studies.GLUE
3rd Annual Guggenheim Healthcare Innovation Conference - A $50M Novartis milestone drove Q3 profit as clinical programs advanced and runway extends into 2029.GLUE
Q3 2026 - MRT-8102 showed potent NEK7 degradation, biomarker normalization, and strong safety in Phase I.GLUE
Study result - Advancing targeted protein degraders in inflammation, autoimmune, and oncology with strong financial runway.GLUE
Wells Fargo 21st Annual Healthcare Conference - Advancing three first-in-class MGD programs with strong pharma partnerships and robust clinical data.GLUE
Corporate presentation - Q2 2026 net loss rose on lower collaboration revenue and higher R&D; cash runway extends to 2029.GLUE
Q2 2026 - Pipeline advances in oncology and autoimmunity set up major clinical milestones for the coming year.GLUE
Jefferies Global Healthcare Conference 2025 - Strong pipeline progress, Novartis deal, and $377M cash position support growth into 2028.GLUE
Q4 2024